Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Steve, I've found this to be a reliable indicator, but there's a trick, enter a short 2 to 3 weeks after the red line takes a dive, the commercials are always early....gg....http://marketpit.com/S&P500.htm
Have you considered trading Dow options?......just use candlesticks to determine direction....gg....http://finance.yahoo.com/q?s=DJVOE.X
Looks like a perfcet set up for a dive....weak dollar, gravestone doji on the Dow yesterday, crude rocking, Bradley turn March 4, Sryia, etc.
I'm on some April 109 dow puts,options on futures,the jumbos, $10 per point per contract..I joined the commercials....gg....http://www.marketpit.com/S&P500.htm
that dern Mahendra's always off a few moon's, but he can pick em......7 come 11...http://www.mahendraprophecy.com/
the equity,real estate top is in, silver and gold have a ways to go .....circa 1932... Big Rock Candy Mountain One evening as the sun went down and the jungle fire was burningDown the track came a hobo hiking and he said boys I'm not turningI'm headin for a land that's far away beside the crystal fountainsSo come with me we'll go and see the Big Rock Candy MountainsIn the Big Rock Candy Mountains there's a land that's fair and brightWhere the handouts grow on bushes and you sleep out every nightWhere the boxcars are all empty and the sun shines every dayOn the birds and the bees and the cigarette treesWhere the lemonade springs where the bluebird singsIn the Big Rock Candy MountainsIn the Big Rock Candy Mountains all the cops have wooden legsAnd the bulldogs all have rubber teeth and the hens lay soft boiled eggsThe farmer's trees are full of fruit and the barns are full of hayOh, I'm bound to go where there ain't no snowWhere the rain don't fall and the wind don't blowIn the Big Rock Candy MountainsIn the Big Rock Candy Mountains you never change your socksAnd the little streams of alcohol come a-trickling down the rocksThe brakemen have to tip their hats and the railroad bulls are blindThere's a lake of stew and of whiskey tooYou can paddle all around 'em in a big canoeIn the Big Rock Candy MountainsIn the Big Rock Candy Mountains the jails are made of tinAnd you can walk right out again as soon as you are inThere ain't no short handled shovels, no axes saws or picksI'm a goin to stay where you sleep all dayWhere they hung the jerk that invented workIn the Big Rock Candy MountainsI'll see you all this coming fall in the Big Rock Candy Mountains « Back to "Miscellaneous Bluegrass Artists" Author: naVersion: Harry McClintockNotes:Lyrics provided courtesy of Bluegrass Lyrics.Com!
Hi Bullwinkle, have you had any luck trading Bradley signals?....I'm trying em out via dow options, there's a signal tomorrow, I'm assuming it's a sell....http://www.amanita.at/e/faq/e-bradley.htm
I don't know how to "read" the two COT graphs that you posted.....When using the marketpit COT data, I look for sharp dives or runups (red line), I've also found that it's best to enter a trade 2-4 weeks after the red line makes a sharp turn, the commercials seem to be a bit early but they usually win out....link to most markets....http://www.marketpit.com/COT%20Charts.htm
Hi bullwinkle, I've been trading commodity options using COT data, pretty cool, I caught the recent gold rally, note rising red line (bullish)...http://www.marketpit.com/Gold.htm I bought some Dow puts today....note plunging red line on SP (bearish),,,,http://www.marketpit.com/S&P500.htm
SP commercials are bailing....got puts?....http://www.marketpit.com/S&P500.htm
I'm doing ENMD trades on the side ( while holding a core position, don't want to miss out on a moonshot) ...ENMD is doing just like ELN did in the winter of 2003, then ELN bottomed around $2 and hit $20 first quarter 2004...According to the script, ENMD bottoms in a couple of weeks, then straight up til June 6.
ONYX wasn't aware of Chinese trials, I wonder if 2me2 trials are being conducted in China.
Chinese use treatment discarded by ONYX, reach a deal....enter cancer in search box...http://story.news.yahoo.com
yep...taxotere (Aventis owns) and panzem=complete response in phase 1 trial
pic of leaky vessels....http://www.med.unibs.it/~airc/sandra/pathology.html
Aaron, the trick to Elan's NCD process is to prevent agglomerating (sticking together) I envision zillions of nanoparticles suspended in a solution without sticking to each other, I wish I knew at what point the nanocrystals dissolve....Thanks for that OXGN post, I'm glad Dr. Kerbel mentioned panzem, him and D'Amato have been doing "blood test" research (post 1701)
I smell what yer cookin....gg...eom
leaky vessels....http://www.cancer.dartmouth.edu/media/release/031903.shtml
Mahendra's going ga ga over silver....note Feb 11 comments.....http://www.mahendraprophecy.com/
Doug Casey on VGZ....http://www.theaureport.com/pub/co/46
Since a healthy trial was conducted, I wonder if the patients in the 1b trial are allowed to start with a higher dosage regimen.
stable disease article....http://www.cancerguide.org/stable_disease.html
Hasn't panzem had better results in mm,prostate,breast trials? Hmm, the trials involved patients with advanced cancer, there's that disease progression catch phrase too...http://www.thedoctorslounge.net/oncolounge/articles/iressa_nsclc/
Mayo is enrolling in old capsule mm trial too, purpose to see if panzem stops progression, could we get FDA approval from stable disease?....see post #1764....http://www.entremed.com/go.cfm?do=Page.View&ID=167 .........
Trials by
Theme
Bone and Muscle Disease ResearchBrain and Nerve Disease ResearchCancer ResearchDigestive Disease ResearchEndocrine and Metabolic Disease ResearchGenomics and Proteomics ResearchHeart, Lung, and Blood ResearchInfectious Disease ResearchKidney and Urological Disease ResearchTransplant Research
A Study of the Efficacy and Safety of 2-Methoxyestradiol to Treat Multiple Myeloma
IRB Number : 2191-00
Trial Status : Open for Enrollment
Why is this study being done?
This study is being done to see if 2-Methoxyestradiol (2ME2), swallowed twice daily, can stop multiple myeloma from progressing. Researchers also expect to learn about the side effects of giving the drug twice a day and to learn how the human body processes 2ME2.
Who is Eligible to Participate in the Study?
Patients with plateau phase or relapsed multiple myeloma may be eligible for this study.
What is Involved With this Study?
To make sure that you can safely take part in this study, there will be two screening visits. At the first one, researchers take your medical history and give you a complete physical exam. You will have a bone marrow aspirate and biopsy, bone survey, and blood tests. At the second, you will have an electrocardiogram, more blood tests, and a urinalysis to make sure you are still eligible for this study.
Before you actually begin taking the study drug, you may have to repeat some of these tests for safety purposes. You will take the 2ME2 twice day for as long as you are on the study.
Before the first dose of drug, and once a month for the first 6 months, special tests will measure the levels of 2ME2 in your blood. The special tests will be repeated at months 9, 12, and 18, then once a year until the study is over -- or until your disease progresses or your doctor decides it is in your best interest to leave the study.
You will have a physical exam, medical history, and the special blood tests once a month for the first six months; at month(s) 9, 12, 18; and then once a year.
How long will the Study run?
You could be in the study as long as the disease does not progress and you have no bad side effects from the study drug.
Who can I Contact for Additional Information on this Trial?
For more information about this study or other cancer studies please email:
Mayo Clinic Comprehensive Cancer Center.
What is/are the Locations of this Clinical Trial?
Rochester, MN
Legal restrictions and terms of use applicable to this site
Use of this site signifies your agreement to the terms of use
Copyright © 2004 Mayo Foundation for Medical Education and Research.
moberylane, I'm kind of thinking the Boston area is in for a three-bagger..Sox,Pats,Harvard.....I hope ENMD rides the wave.
bounce time?....enter ENMD....http://www.stock100.com/
funny, a guy I follow has symbol in name...raymoND MErriman,....http://www.mmacycles.com/fc2005.htm
no phase, a study to see if 2me2 stops mm from progressing?....enrolling?....old info?....http://www.mayoclinic.org/multiple-myeloma/clintrials.html
ENMD cycles, a couple of cycles converge Feb 05....to see print max chart from yahoo, get a ruler....1997 low to 1998 moonshot is equal to 2004 low and Feb 05....1998 high to 2000 high is equal to 2003 moonshot to Feb 05....could see some fireworks soon...gg
NCI nanodevice page....do a google....understanding cancer series: nanodevice
bingo... " The larger surface area provided by quantum dots should allow the conjugation of multiple agents"...from post #1571 link
C-peptide, thanks for the clarification. I guess nanocrystal is fancy for finely ground. The trick to Elan's process is a step that prevents agglomerating (clumping). That's too bad there's not a delivery system that takes advantage of the leaky vascular.
Aaron, we need to get to the bottom of this...gg...I'm a bit confused, the new formulation is made up of very fine particles to increase the surface area. Is panzemNCD dissolved before it reaches the tumor? Will that overcome the interstitial fluid pressure problem? Do the Winship quantom dots and West nanoshells, which accumulate near tumors, stay intact until they reach the tumor? Does the liquid suspension allow the new panzem to reach the tumor intact?
InternistMD...I stand corrected, I thought the new panzem utilized passive targeting........ 3. Passive targeting Passive targeting is technology used to accumulate drugs on the target regions, which stimulates living bodies' functions by increasing stability in the body during the process whereby the drugs dosage exerts its effect. Enhanced Permeability and Retention EffectLow molecular weight drugs permeate through the blood capillaries and reach all organs in varying degrees. Materials made up of less than 30,000 molecules quickly get discharged from bodies after renal glomerular filteration. By multiplying themselves, cancer tissues cause production of new vessels with poor structural ability. The blood permeability surrunding the cancer tissue is as large as three to ten times compared to the normal tissue because of the dysfunction of the blood and the presense of VEGF. Therefore, polymer molecules and nanoparticles easily permeate and accumulate in cancer tissues. Furthermore, lymph vessels of cancer tissues are immature or absent. In general, while leaked polymer molecules or nanoparticles in normal tissues move to lymph vessels and get discharged, they remain for a long time in cancer tissues after the leakage. As a result, polymer molecules and micro particles have a tendency to accumulate around cancer tissues, which means that anti-cancer drugs if maintained stably within micellar nanoparticles would accumulate on cancer tissues.
leaky vessels getting some press today....nanospheres accumulate near tumors....enter "nanomedicine" in search box....Washington Post article...http://dailynews.yahoo.com/
Folkman on leaky vessels....two links....http://focus.hms.harvard.edu/2004/March19_2004/oncology.html ....http://www.nanocarrier.co.jp/d2_e.html
another AI success, I hope this trend starts to lift all AI boats....http://www.pharmabiz.com/article/detnews.asp?articleid=25907
Millions of cancer patients are alive today because of the care and expertise their oncologists have employed in administering high dose chemotherapy. The underlying rational has been to use the most effective chemo or chemo combinations at as high a dose possible in order to kill the most cancer cells... without killing the patient. However, 45% of cancer patients eventually succumb to their disease. When cancer becomes completely chemo resistant and high dose chemotherapy is no longer a viable option, is there anything left for patients and their doctors to try? Drs. Timothy Browder, Robert Kerbel, and Judah Folkman think there is... Sequential Low-Dose Chemotherapy.The idea that chemotherapy given at lower doses may be effective where higher doses have failed at first seems implausible. The explanation offered is that the low-dose treatments do not target the tumor cells directly but the capillaries that nourish them. "In de-emphasizing the tumor cell as a target, this strategy requires a fundamental change in our approach to therapy," observes the University of California's Douglas Hanahan, A major benefit from using lower doses is that patients report fewer or no side affects. In reporting on trials run at the European Institute of Oncology, Dr. Aron Goldhersch agreed. "We see very little toxicity on white blood cells. We don't see serious nausea. We don't see vomiting."In most low-dose studies conducted up to now, even when tumors have disappeared completely, they eventually return and patients die. The explanation for the improved results appear to lie in Folkman's discovery that it is necessary to add other antiangiogenic drugs to the regimen."If you're a clinician and you want to do something," Kerbel said "you've got three choices: interferon, thalidomide, and the COX-2 inhibitors."An example of a sequential low-dose regimen:Antiangiogenic DrugsInterferon alpha 1 million units daily Thalidomide 50 mg daily, 1/2 hour before bedtime.Celebrex 200mg, twice daily In addition to the above, on a rotating basis: Weeks 1-3 cytoxan 400mg/m2 once a weekWeeks 4-6 taxol 80-90mg/m2 once a weekWeeks 7-9 VP16 50 mg dailyAnecdotal clinical experience and laboratory studies in animal models suggests that changing chemotherapy agents every 2-3 weeks may be most effective in attacking tumors' blood supply. Recent anecdotal clinical experiences with drug resistant tumors have shown stabilization using Cytoxan 400mg/M2 weekly for 3 weeks, followed by taxol 80-90mg/M2 weekly for 3 weeks, followed by oral etoposide 50mg. orally daily for 3 weeks (or dose adjusting to titrate the WBC to between 2,000 and 3,000.) then repeating the cycle. If tumor sensitivities are known or likely, based on tumor type, it would make sense to use these agents sequentially which also may share tumor cell cytotoxicity for 3 weeks each, then repeating the cycle. (Note: etoposide is the only of these agents used more often than every 6-7 days).When anti-angiogenic chemotherapy is applied in patients who have already depleted copper levels below the angiogenic threshold, but have not yet achieved tumor stabilization, their bone marrow shows greater sensitivity to these chemotherapeutic agents. In such situations it is best to use the above doses of these agents as total dose, rather than as a per meter squared dose, and check the CBC prior to each repeat dose of chemotherapy. Copper depleted patients will not likely tolerate etoposide (oral or IV) more often than every 6 days. If red cell growth factor support is needed, give Procrit 40,000 units the day after chemotherapy on a weekly basis. If WBC support is needed, give GMCSF (Leukine) 500 mcg. daily starting the day after chemotherapy and stopping 48 hrs. before the next dose of chemotherapy (i.e. for 3 or 4 days between doses, depending if the interval between chemotherapy doses is 6 or 7 days. Chemotherapy doses should also be attenuated as needed to maintain blood counts. If cytopenias are severe, it is better to give a very small dose of chemotherapy followed by growth factor support, than to skip doses, as endothelial cell damage from chemotherapy agents repairs very quickly. The regimen should be given continuously without stop. Sequential low-dose chemotherapy is directed at inhibiting new capillary growth. Slight tumor growth may occur during the first few weeks (supported by the existing capillary bed). Tumor shrinkage should occur ONLY as the existing capillaries break and are not replaced.Click on links below to learn more."Cancer-drug treatment: Less might prove more" This is an article in the Chicago Tribune dated 4/2/2000 discussing the April 2000 meeting of the American Association for Cancer Research."New drug regimen buoys cancer doctors" Here is an article from The Toronto Star, dated 2/26/2000 relating to Dr. Kerbel's studies with low dose chemotherapy."'Accidental' anti-angiogenesis drugs"This is an abstract of an article by Robert Kerbel, published June 10, 2000 in the European Journal of Cancer."Giving Smaller Doses Of Chemotherapy More Frequently May Attack Tumor Blood Supply"This article is from Science Daily which was reprinted from a Jefferson Medical College news release dated March 27, 2001."Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity"This is an article from the Journal of Clinical Investigation by Giannoula Klement, et al., published online March 31, 2000.Home / Angiogenesis / Angiogenesis and Cancer / Role of CopperCopper Lowering Protocol / FAQS About Copper Protocol / Low Dose ChemotherapyAngiogenesis Inhibitors / Action Steps / Glossary / Links / About Us
I did not know that....http://www.freerepublic.com/focus/f-news/1328262/posts